We are live on
!
Find out more
NTC
North Tide Capital Portfolio holdings
AUM
$469M
1-Year Est. Return
6.57%
This Fund
S&P 500
This Quarter
Est. Return
+3.4%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$63.3M
(+4.8%)
Cap. Flow
+$76.7M
Cap. Flow
% of AUM
5.54%
Top 10 Holdings %
Top 10 Hldgs %
74.96%
Holding
28
New
8
Increased
3
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$92.5M |
| 2 |
Gilead Sciences
GILD
|
+$54.6M |
| 3 |
SVU
SUPERVALU Inc.
SVU
|
+$52.4M |
| 4 |
Quest Diagnostics
DGX
|
+$36.9M |
| 5 |
STJ
St Jude Medical
STJ
|
+$36.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$79.9M |
| 2 |
Bausch Health
BHC
|
+$49.7M |
| 3 |
GHDX
Genomic Health, Inc.
GHDX
|
+$45.8M |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
+$43.4M |
| 5 |
Baxter International
BAX
|
+$34.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.39% |
| 2 | Consumer Discretionary | 3.6% |
| 3 | Technology | 3.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
1
DELISTED
Select Medical
SEM
| $211M | 15.2% |
24,128,000
-835,200
| -3% | -$7.01M |
|
|
2
Teva Pharmaceuticals
TEVA
$37.3B
| $177M | 12.8% |
3,000,000
+1,500,000
| +100% | +$92.5M |
|
|
AMED
3
DELISTED
Amedisys
AMED
| $159M | 11.47% |
4,000,000
| – | – |
|
|
KND
4
DELISTED
Kindred Healthcare
KND
| $101M | 7.32% |
5,000,000
-513,999
| -9% | -$11.8M |
|
|
SVU
5
DELISTED
SUPERVALU Inc.
SVU
| $101M | 7.3% |
1,785,714
+785,714
| +79% | +$52.4M |
|
6
Viatris
VTRS
$20.1B
| $67.9M | 4.9% |
1,000,000
| – | – |
|
7
Community Health Systems
CYH
$465M
| $63M | 4.55% |
1,210,000
-605,000
| -33% | -$27.1M |
|
|
8
Gilead Sciences
GILD
$167B
| $58.5M | 4.23% |
+500,000
| New | +$54.6M |
|
|
AFAM
9
DELISTED
Almost Family Inc
AFAM
| $49.9M | 3.6% |
1,250,000
| – | – |
|
10
Orthofix Medical
OFIX
$468M
| $49.7M | 3.59% |
1,500,000
-300,000
| -17% | -$10.3M |
|
|
TVTY
11
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $46.1M | 3.33% |
3,850,000
| – | – |
|
|
STJ
12
DELISTED
St Jude Medical
STJ
| $36.5M | 2.64% |
+500,000
| New | +$36.1M |
|
|
13
Quest Diagnostics
DGX
$23.3B
| $36.3M | 2.62% |
+500,000
| New | +$36.9M |
|
|
MGLN
14
DELISTED
Magellan Health Services, Inc.
MGLN
| $35M | 2.53% |
500,000
| – | – |
|
|
ELOS
15
DELISTED
Syneron Medical Ltd
ELOS
| $31.9M | 2.3% |
3,000,000
| – | – |
|
16
Align Technology
ALGN
$12.7B
| $31.4M | 2.26% |
+500,000
| New | +$29.5M |
|
|
IMS
17
DELISTED
IMS HEALTH HLDGS INC COM STK (DE)
IMS
| $30.6M | 2.21% |
+1,000,000
| New | +$29M |
|
18
Labcorp
LH
$23.2B
| $30.3M | 2.19% |
+291,000
| New | +$30.3M |
|
|
VVUS
19
DELISTED
Vivus Inc
VVUS
| $29.5M | 2.13% |
1,250,000
| – | – |
|
|
AEGR
20
DELISTED
Aegerion Pharmaceuticals
AEGR
| $19M | 1.37% |
1,000,000
+700,000
| +233% | +$15.2M |
|
|
NXGN
21
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $16.6M | 1.2% |
+1,000,000
| New | +$16.1M |
|
22
Option Care Health
OPCH
$3.41B
| $3.63M | 0.26% |
+250,000
| New | +$4.23M |
|
|
23
Baxter International
BAX
$11.7B
| – | – |
-920,500
| Closed | -$34.3M |
|
|
24
Bausch Health
BHC
$1.8B
| – | – |
-250,000
| Closed | -$49.7M |
|
|
25
Boston Scientific
BSX
$65.4B
| – | – |
-4,500,000
| Closed | -$79.9M |
|
Similar funds
SD
DG
NBC
JWM
JPCCM
MCL
GIIO
FC
North Tide Capital's Q2 2015 Portfolio in Review
As of Q2 2015, North Tide Capital held 28 positions worth $1.39B, up 4.8% from $1.32B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
North Tide Capital deployed $76.7M of net new capital in Q2 2015, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Gilead Sciences: 500,000 shares worth $58.5M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 83% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Community Health Systems, an estimated $27.1M trimmed.
- North Tide Capital's largest Q2 2015 buy was Gilead Sciences: 500,000 shares worth $58.5M.
- North Tide Capital added most to Teva Pharmaceuticals in Q2 2015, an estimated $92.5M increase.
- North Tide Capital's biggest Q2 2015 reduction was Community Health Systems, cutting an estimated $27.1M.
- North Tide Capital fully exited Boston Scientific in Q2 2015, selling an estimated $79.9M.
- North Tide Capital's ten largest holdings make up 75% of its $1.39B portfolio in Q2 2015.
- North Tide Capital opened 8 new positions and closed 6 in Q2 2015.
- North Tide Capital's portfolio value rose 4.8% quarter-over-quarter to $1.39B.
Based on North Tide Capital's 13F filing for Q2 2015, filed 14 Aug 2015.